ArticleOrphanet journal of rare diseases2025
Healthcare utilization and disease burden in children with metachromatic leukodystrophy in Germany.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical management of metachromatic leukodystrophy cases identified in the German and Austrian Newborn screening pilots.Orphanet journal of rare diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetachromatic leukodystrophy (MLD) is a life-limiting neurodegenerative disease due to pathogenic variants in the ARSA gene. Patients experience severe neurological symptoms, developmental regression, and early death. Aim of the study was to analyze disease burden and healthcare utilization in different stages of the disease in children with late infantile and juvenile MLD in Germany.
methodsOut of a nationwide total cohort study (TC) (n = 83), we undertook telephone interviews in a representative follow-up cohort (FC) defined by advanced disease stages (n = 19). The FC allowed detailed long-term data of the disease in addition to cross-sectional data of the TC.
resultsNearly all patients showed spasticity, truncal hypotonia and dysphagia, and about half of the patients developed epilepsy. Most children required special education; none finished regular school. Analysis of the FC showed that neuronal intestinal burden was extensive, including obstipation (57%), micturition problems (47%), and tube feeding (63%). Gallbladder polyposis was seen in 52%. General well-being did not strongly correlate with motor function, whereas pain was associated with reduced well-being. Baclofen, Omeprazole, Vigabatrin and Polyethyleneglycol were the most frequently used drugs. Patients took up to 15 different drugs daily. Altogether, 127 hospitalisations (485 treatment days) were registered in the FC (median age 9 years, median one inpatient stay per patient per year). Diagnostic procedures were main reasons for hospitalization (29 hospitalizations, 128 treatment days), and accounted for the main burden for families (68%). The median use of 15 different devices (maximum 29) throughout life illustrated a high burden of the disease. During disease course, there was a change from more "active" devices (e.g., walker) to more "passive" devices (e.g., form seat). Physical therapy was the most relevant therapy in advanced disease stages (100%), while occupational therapy or speech therapy primarily were used in early disease stages. State welfare benefits, home- and palliative care were used broadly.
conclusionDiagnostic and treatment routine pathways and sociomedical support in MLD require extensive resources. We provide detailed cross-sectional and long-term data of MLD-associated disease burden in different stages of disease. This data may serve as a reference when analyzing disease- and healthcare burden also after gene-/stem cell-therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.